Breakfast breakthrough: kidney cancer drug may work better with morning meal

This study looked at whether taking the kidney cancer drug cabozantinib with a light breakfast could reduce side effects like nausea and diarrhea, and possibly allow patients to skip doses sometimes. Twelve adults with advanced kidney cancer who were already on a stable dose of cabozantinib took the drug both with and without breakfast to compare how much of the drug got into their blood. The goal was to find a better dosing schedule that is easier for patients and may lower costs.